Long gonadotrophin releasing hormone agonist/human menopausal gonadotrophin protocol for ovarian stimulation in intrauterine insemination treatment

Eur J Obstet Gynecol Reprod Biol. 1997 Jul;74(1):83-7. doi: 10.1016/s0301-2115(97)00086-9.

Abstract

Objective: This prospective study was undertaken to examine the usefulness of a long gonadotrophin releasing hormone agonist (GnRH-a)/human menopausal gonadotrophin (hMG) protocol in intrauterine insemination (IUI) treatment. The results were compared to those of clomiphene citrate (CC)/hMG/IUI.

Study design: Seventy-five patients were recruited to a GnRH-a/hMG group (group 1) while 88 patients underwent CC/hMG stimulation and served as controls (group 2). The study subjects were stimulated with a long GnRH-a/hMG regimen. IUI was performed 36 h after the administration of human chorionic gonadotrophin.

Results: The number of preovulatory follicles, the thickness of endometrium and sperm parameters were similar in both groups. The hMG requirements were significantly higher in group 1 than in group 2 (21.2 +/- 5.1 vs. 8.1 +/- 3.1 ampoules). The pregnancy rate was 20% in group 1 and 12.5% in group 2, the difference being not significant.

Conclusion: The pregnancy rates were not significantly different between the GnRH-a/hMG/ IUI and CC/hMG/IUI groups. In addition, GnRH-a/hMG stimulation is notably more expensive than CC/hMG, and for these reasons, GnRH-a/hMG stimulation is not cost-effective in routine IUI therapy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Buserelin / administration & dosage*
  • Buserelin / therapeutic use
  • Clomiphene / administration & dosage
  • Female
  • Fertilization in Vitro
  • Humans
  • Infertility / therapy
  • Insemination, Artificial, Homologous*
  • Male
  • Menotropins / administration & dosage*
  • Menotropins / therapeutic use
  • Ovulation Induction*
  • Pregnancy
  • Pregnancy, Multiple
  • Prospective Studies

Substances

  • Clomiphene
  • Menotropins
  • Buserelin